148 related articles for article (PubMed ID: 38494800)
21. [Unresectable Esophageal Cancer on the Elderly Woman Which Was Treated Effectively with Ipilimumab plus Nivolumab-A Case Report].
Fujii T; Suzuki T; Yamaguchi S; Shibata Y; Tazuma S; Akimoto S; Sada H; Shimada N; Tazawa H; Onoe T; Sudo T; Shimizu Y; Tashiro H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1691-1693. PubMed ID: 38303175
[TBL] [Abstract][Full Text] [Related]
22. The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy.
Ikeda G; Yamamoto S; Kato K
Expert Opin Drug Saf; 2022 Jan; 21(1):55-65. PubMed ID: 34263677
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.
Ikeda G; Miyakoshi J; Yamamoto S; Kato K
Future Oncol; 2024 Apr; 20(11):665-677. PubMed ID: 38126175
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
26. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N
BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K; Ajani JA; Moehler M; Garrido M; Gallardo C; Shen L; Yamaguchi K; Wyrwicz L; Skoczylas T; Bragagnoli AC; Liu T; Tehfe M; Elimova E; Bruges R; Zander T; de Azevedo S; Kowalyszyn R; Pazo-Cid R; Schenker M; Cleary JM; Yanez P; Feeney K; Karamouzis MV; Poulart V; Lei M; Xiao H; Kondo K; Li M; Janjigian YY
Nature; 2022 Mar; 603(7903):942-948. PubMed ID: 35322232
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
31. [A Case of Locally Advanced Unresectable Esophageal Cancer Treated with Nivolumab and Ipilimumab Therapy Followed by Surgery].
Kakuta R; Chiba T; Shinohara H; Sugishita T; Miura T; Murase H; Hayashi K; Noguchi N; Yokosuka T; Konda A; Miura A; Iseki H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1697-1699. PubMed ID: 38303177
[TBL] [Abstract][Full Text] [Related]
32. A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study).
Shiraishi Y; Hakozaki T; Nomura S; Kataoka T; Tanaka K; Miura S; Sekino Y; Ando M; Horinouchi H; Ohe Y; Okamoto I
Clin Lung Cancer; 2022 Jun; 23(4):e285-e288. PubMed ID: 34802879
[TBL] [Abstract][Full Text] [Related]
33. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
[TBL] [Abstract][Full Text] [Related]
34. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y;
Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063
[TBL] [Abstract][Full Text] [Related]
35. Emerging data on nivolumab for esophageal squamous cell carcinoma.
Hirose T; Yamamoto S; Kato K
Expert Rev Gastroenterol Hepatol; 2021 Aug; 15(8):845-854. PubMed ID: 34251958
[TBL] [Abstract][Full Text] [Related]
36. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
[TBL] [Abstract][Full Text] [Related]
37. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Sakata T; Yatsuzuka N; Doi T; Kato K
Esophagus; 2022 Oct; 19(4):683-692. PubMed ID: 35668304
[TBL] [Abstract][Full Text] [Related]
38. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
40. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
